- ongoing, recruitingTherapeutic use (Phase IV)
A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM).
This study is looking at how well two different medicines, Voltfast and Vydura, work to stop a migraine attack. Researchers want to see how many people are completely free of pain two hours after taking their medicine, and if they need other pain relief.
Denmark - active not recruitingPHASE3
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
This study compares two medicines, atogepant and topiramate, for preventing migraine headaches. Researchers want to see which medicine causes fewer side effects in adults with migraines. It involves taking pills and having regular check-ups over a long period.
Austria · Belgium · Canada - active not recruiting
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
This study looks at how well a medication called atogepant works for adults with migraine in everyday life. If you're prescribed atogepant, you might be asked to join. It simply involves attending your usual doctor's appointments and won't add extra hassle.
United States · Belgium · Canada - enrolling by invitationPHASE1, PHASE2
Self-acupuncture for Migraines Feasibility Study
This study looks at whether people with migraines can learn to do acupuncture on themselves. It's for those who found acupuncture helpful at the Royal London Hospital for Integrated Medicine. We want to see if self-acupuncture is practical, safe, and effective for managing migraine pain.
United Kingdom - active not recruiting
Consistency of Response With Rimegepant in Acute Treatment of Migraine
This study looks at how well a migraine medicine called rimegepant works for people in the UK. If you already use rimegepant for your migraine attacks, you can share your daily experiences for 12 weeks to help us understand its effects better.
United Kingdom - active not recruitingPHASE3
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
This study is testing a tablet called atogepant for treating migraine attacks. It aims to see if it's safe and effective at stopping migraines quickly. Atogepant is already approved for preventing migraines. Around 1300 adults aged 18-75 will take part worldwide.
Belgium · China · Czechia - active not recruitingPHASE3
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
This study is looking at a new medicine called erenumab to see if it can help prevent migraine headaches in children and teenagers aged 6 to 17. We want to find out if it's safe and if it can reduce how often young people get migraines.
United States · Belgium · Canada - ongoing, recruitingTherapeutic confirmatory (Phase III)
H8H-MC-LAHW: A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2
This study, called PIONEER-PEDS2, is looking at a new medicine called Lasmiditan for children and teenagers with migraine headaches. It wants to see how safe the medicine is and if it causes any side effects over a year, specifically for each migraine attack treated.
France · Germany · Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
H8H-MC-LAHV: Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine: PIONEER-PEDS1
This study called PIONEER-PEDS1 is looking at a new medicine called lasmiditan to help children and teenagers with migraine headaches. It compares different doses of lasmiditan with a dummy pill (placebo) to see how well it works to stop pain. This is a big final stage study.
Netherlands · Germany · Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, dose-finding trial of Lu AG09222 for the prevention of migraine in participants with episodic and chronic migraine. Lundbeck trial no: 20297A
This study is testing a new medicine, Lu AG09222, to see if it can help prevent migraines. It's for people who get migraines often, including those with episodic (comes and goes) and chronic (very frequent) migraine. Researchers want to find the best dose to reduce migraine days.
Hungary · Lithuania · Slovakia - ongoing, recruitingTherapeutic use (Phase IV)
MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRP-Antibody treatment – a randomized, controlled, open-label trial.
This study looks at how a new migraine medicine called Ajovy changes brain chemistry. Researchers are using special MRI scans to see if it affects chemicals in the brain that are linked to migraine, and if this helps reduce headaches.
Austria - ongoing, recruitingTherapeutic use (Phase IV)
The rimegePant in RElation to obeSiTy in mIGrainE study
This study looks at how a new migraine medication, rimegepant, works differently in people depending on their body weight. Researchers are checking how it affects blood flow in the skin after applying a special cream and using a small electrical pulse.
Netherlands - authorisedPhase III and phase IV (Integrated)
(WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
This study is looking at how two treatments, a common hormone pill (like Microgynon 30) and vitamin E, compare for women who get migraines linked to their period or during menopause. Researchers want to see if these treatments can reduce how often and how severely these migraines happen.
Netherlands - recruitingPHASE3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
This study is looking at the long-term effects of a medicine called eptinezumab in children and teenagers (aged 6 to 17) who experience migraine headaches. It's for those who have already taken part in a previous migraine study with this medication.
United States · Argentina · Canada - authorisedPhase III and phase IV (Integrated)
Prestige 2- RimegePant in RElation to obeSiTy in miGainE
This study is looking at how well a migraine medicine, VYDURA 75 mg, works for people, especially considering their weight. It aims to see if it stops headaches or other bad migraine symptoms within two hours.
Austria